Apollomics is developing a suite of next-generation therapies to treat cancer. Developing clinical assets requires rigorous preclinical studies and mechanistic and scientific rationale whether the asset is to be used as a monotherapy, a combination therapy or both. Apollomics is using this approach to build a pipeline of therapeutics that fall into three categories:  anti-cancer enhancers,  tumor inhibitors and  immuno-oncology drugs. Apollomic’s lead candidate, APL-101, is a selective and potent, orally-available inhibitor of c-Met, which is overexpressed or mutated in several tumor types. Following successful preclinical and Phase 1 clinical trials, Apollomics is now testing APL-101 in patients with non-small cell lung cancer.
Claim company profile to post jobs directly on this page and this website.